Oncology Biosimilars Market Valuation to Triple by 2033, According to Persistence Market Research

The oncology biosimilars market is poised for rapid growth, driven by the increasing prevalence of cancer, the rising demand for cost-effective biologic therapies, and the expiration of patents for major oncology biologics. The global oncology biosimilars market is projected to grow from US$ 9.2 billion in 2026 to US$ 31.3 billion by 2033, reflecting a compound annual growth rate (CAGR) of 19.1% during the forecast period from 2026 to 2033. This growth is indicative of a larger trend towards biosimilar adoption in cancer treatment, making it a pivotal segment in the global healthcare industry.

Download Your Free Sample & Explore Key Insights: https://www.persistencemarketresearch.com/samples/36352

Key Market Drivers and Growth Indicators
Increasing Cancer Prevalence

Cancer remains one of the leading causes of death globally, with nearly 10 million deaths recorded in 2022 alone. The World Health Organization (WHO) reports that cancer cases are steadily rising, prompting a demand for both innovative and affordable treatment options. As healthcare systems worldwide face mounting pressure from the growing cancer burden, the shift toward biosimilars-biologic drugs that are highly similar to the original, reference biologic medicines-has gained significant traction.

Biosimilars provide a cost-effective alternative to original biologics, which are often prohibitively expensive. As the demand for cancer treatment continues to increase, the role of biosimilars in making these therapies more accessible to patients has become critical. For instance, biosimilars offer savings of up to 30% compared to their reference biologics, thus playing an essential role in improving treatment accessibility while reducing healthcare costs.

Patent Expirations of Oncology Biologics

A key factor contributing to the growth of the oncology biosimilars market is the expiration of patents for several high-revenue biologic drugs. Many blockbuster oncology drugs, such as trastuzumab (Herceptin), rituximab (Rituxan), and bevacizumab (Avastin), are facing patent expirations, providing opportunities for biosimilar manufacturers to step in. As a result, biosimilars of these widely used drugs have become increasingly available, further expanding the market and providing cost-effective alternatives for patients worldwide.

Supportive Regulatory Frameworks

Governments and regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have played a key role in fostering the growth of the oncology biosimilars market by establishing clear approval pathways. These agencies have recognized the need for affordable cancer treatments, leading to the approval of several oncology biosimilars in recent years. With more regulatory frameworks in place, the path to biosimilar commercialization is smoother, and manufacturers are encouraged to invest in biosimilar development.

Dominant Drug Class Segment: Monoclonal Antibodies

Monoclonal antibodies (mAbs) dominate the oncology biosimilars market, accounting for 45.1% of the market share in 2025. This class of drugs includes biosimilars of blockbuster biologic therapies such as trastuzumab, rituximab, and bevacizumab, which are used to treat various cancers, including breast cancer, lymphoma, and colorectal cancer. As these patents expire, biosimilar versions of these therapies have gained significant market share.

Monoclonal antibodies work by targeting specific cancer-related proteins, blocking tumor growth pathways, and boosting the immune system's ability to fight cancer cells. Given their proven efficacy and widespread clinical use, monoclonal antibody biosimilars are poised for continued growth. The increasing demand for targeted cancer therapies, along with the expiration of patents for originator biologics, has positioned monoclonal antibody biosimilars as a key growth driver in the oncology biosimilars market.

Regional Market Insights
North America: Market Leader

North America holds a dominant position in the oncology biosimilars market, accounting for approximately 38.7% of the market share in 2025. The United States, in particular, is a major player due to its strong healthcare infrastructure, high cancer burden, and favorable regulatory environment. The U.S. FDA has approved more than 80 biosimilars, many of which are used in oncology and autoimmune diseases. Additionally, the Biologics Price Competition and Innovation Act (BPCIA) has facilitated the entry of biosimilars into the market by establishing a clear regulatory pathway for their approval.

Government initiatives, such as those focused on reducing healthcare costs and encouraging biosimilar adoption, have further boosted the growth of biosimilars in North America. The increased acceptance of biosimilars among physicians and healthcare providers is also contributing to the market's expansion, making North America a key region for oncology biosimilars.

Get Custom Insights Designed for Your Businecss: https://www.persistencemarketresearch.com/request-customization/36352

Europe: Early Adoption and Regulatory Support

Europe is a significant player in the oncology biosimilars market, thanks to its early adoption of biosimilars and a robust regulatory framework established by the European Medicines Agency (EMA). Europe was the first region to approve biosimilars for oncology use, and by 2024, more than 100 biosimilars had been approved in the region. This regulatory encouragement has led to widespread clinical use and the adoption of biosimilars in hospitals across Europe.

Moreover, many European countries have implemented policies to promote the use of biosimilars, including tender-based procurement and biosimilar substitution programs. These initiatives, combined with the region's high cancer burden, which sees approximately 2.7 million new cancer cases diagnosed annually, have created a strong demand for cost-effective oncology treatments, further accelerating the growth of the biosimilars market.

Asia-Pacific: Fastest-Growing Region

The Asia-Pacific region is the fastest-growing market for oncology biosimilars, driven by the high cancer incidence, improving healthcare access, and growing local biosimilar manufacturing. According to global cancer statistics, the Asia-Pacific region accounts for nearly 50% of new cancer cases worldwide, underscoring the vast potential for biosimilars in the region.

Countries such as China, India, Japan, and South Korea are investing heavily in biosimilar development and manufacturing, with governments supporting biosimilar access through favorable policies and healthcare programs. As biosimilar monoclonal antibodies gain traction in these markets, the demand for cost-effective cancer therapies is expected to rise rapidly, making Asia-Pacific a key growth region for oncology biosimilars.

Market Restraints: High Development and Manufacturing Costs

Despite the promising growth prospects, the oncology biosimilars market faces significant challenges. The development and manufacturing of biosimilars are complex and expensive. Unlike traditional generic drugs, which are chemical in nature, biosimilars are biologic products derived from living cells. This complexity makes the production process highly regulated and technically challenging.

Developers must conduct extensive clinical trials and comparability studies to demonstrate the similarity between the biosimilar and the reference biologic. This process increases both development time and financial risk, making biosimilar development a costly venture. The high upfront investment required to develop biosimilars remains a key restraint for many pharmaceutical companies, limiting the number of new players entering the market and slowing the pace of new oncology biosimilars being introduced.

Market Opportunities: Expanding Biosimilar Pipeline

One of the most significant opportunities in the oncology biosimilars market lies in the expanding pipeline for monoclonal antibodies. As several blockbuster biologics approach patent expiration, biosimilar manufacturers are capitalizing on the opportunity to develop lower-cost alternatives. In particular, the availability of biosimilars for trastuzumab, rituximab, and bevacizumab has already demonstrated strong market uptake, with adoption rates reaching approximately 80% in some markets.

Looking ahead, a large number of biologic cancer therapies are expected to lose exclusivity over the next decade, providing ample opportunities for new biosimilar entrants. With increasing government support for biosimilar adoption, the growing availability of biosimilars will likely enhance patient access to advanced cancer treatments.

Get Custom Insights Designed for Your Businecss: https://www.persistencemarketresearch.com/request-customization/36352

Market Segmentation

By Drug Class

Monoclonal Antibodies (mAbs)
Granulocyte Colony-Stimulating Factor (G-CSF)
Erythropoiesis-Stimulating Agents (ESAs)
Others

By Indication

Breast Cancer
Lung Cancer
Colorectal Cancer
Cervical Cancer
Blood Cancer
Others

By Route of Administration

Intravenous (IV)
Subcutaneous (SC)
Others

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

By Region

North America
Europe
East Asia
South Asia & Oceania
Latin America
Middle East and Africa

Competitive Landscape

The oncology biosimilars market is highly competitive, with major biopharmaceutical companies such as Pfizer, Novartis (Sandoz), Viatris, Amgen, and Samsung Bioepis leading the charge. These companies are focused on biosimilar development, regulatory approvals, strategic collaborations, and expanding manufacturing capabilities to meet the growing demand for cost-effective cancer therapies. These industry giants are working to strengthen their portfolios of oncology biosimilars, positioning themselves for long-term success in this rapidly growing market.

Key Industry Developments

In September 2025, Novartis entered into a collaboration with Monte Rosa Therapeutics to develop protein degrader therapies aimed at treating cancer and other serious diseases. Similarly, in July 2025, Pfizer signed a licensing agreement with 3SBio to expand its biosimilar portfolio in China, highlighting the increasing focus on expanding biosimilar development in emerging markets.

Conclusion

The oncology biosimilars market is set to experience significant growth in the coming years, fueled by increasing cancer prevalence, patent expirations of major biologics, and the growing demand for cost-effective therapies. With monoclonal antibodies leading the charge, the market is expected to see expanding biosimilar pipelines, especially as more cancer therapies lose patent protection. While challenges remain, such as high development costs, the market's overall outlook is positive, offering substantial opportunities for pharmaceutical companies and healthcare systems to improve patient access to life-saving cancer treatments.

Contact Us:

Persistence Market Research
Second Floor, 150 Fleet Street, London, EC4A 2DQ, United Kingdom
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web: https://www.persistencemarketresearch.com

About Persistence Market Research:

At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.

Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.

This release was published on openPR.